Search Results

Test Catalog

CSMTU - Overview: Controlled Substance Monitoring Targeted Profile, 17 Drug Classes, Mass Spectrometry, Random, Urine

Detecting drug use involving stimulants, benzodiazepines, and opioids This test is not intended for use in employment-related testing.

ALDU - Overview: Aldosterone, 24 Hour, Urine

Investigating primary aldosteronism (eg, adrenal adenoma/carcinoma and adrenal cortical hyperplasia) and secondary aldosteronism (renovascular disease, salt depletion, potassium loading, cardiac failure with ascites, pregnancy, Bartter...

JAK2V - Overview: JAK2 V617F Mutation Detection, Varies

Aiding in the distinction between a reactive blood cytosis and a chronic myeloproliferative disorder using extracted DNA specimens

Site Search

Mayo Clinic Ranked No. 1 Hospital Nationwide by U.S. News & World Report - Insights

Report’s 29th annual "Best Hospitals Honor Roll" published online on August 14. Mayo Clinic also ranked No. 1 in more specialties than any other hospital in the country....

NELL-1 [Test in Focus] - Insights

D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic...

Looking Back on Clinical Chemistry 1 - Insights

in the Mayo Clinic Medical Laboratory Science program, takes a look back on her Clinical Chemistry 1 course....

Detection of (1→3)-𝝱-D-glucan as a Marker of Invasive Fungal Disease - Insights

In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the detection of (1→3)-β-D-glucan (BDG) in serum as a biomarker for the presence of invasive fungal infections....

Orexin-A/Hypocretin-1 for the Diagnosis of Type 1 Narcolepsy [Test in Focus] - Insights

test to perform as well as to interpret. The orexin-A/hypocretin-1 test is a sensitive and specific alternative to the MSLT to diagnose type 1 narcolepsy....